Info

🌱 來自: metastatic breast cancer

Epidemiology of metastatic breast cancer

• 6% of breast CA is met at dx (SEER Cancer Stats Review 1975–2013)
• HR+/HER2- ~60%, HR-/HER2+ ~10%, HR+/HER2+ ~15%, TNBC ~15%
• Risk of BC recurrence after local Rx greatest in 1st 3 yrs but persists for decades, w/HER2+/TNBC pts at highest risk for early recurrence & ER+ for late (JCO 2016;34:927)
• Most common met sites: Lung (esp TNBC), bone (esp ER+), liver, & adrenal gland